Business Context and Reporting Period
Company: Onkure Therapeutics, Inc. (OKUR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Onkure is a clinical-stage biopharmaceutical company developing precision medicines targeting specific mutations in the PI3Kα gene, primarily for breast cancer. The company's lead candidate, OKI-219, is a highly selective inhibitor of the PI3Kα H1047R mutation. The company completed a reverse recapitalization merger with Reneo Pharmaceuticals in October 2024. As of the filing date, the company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(59,517) | $(52,673) |
| Operating Expenses | $62,950 | $54,386 |
| Cash and Cash Equivalents (Year End) | $59,050 | $110,761 |
| Accumulated Deficit | $(214,241) | $(154,724) |
| Net Cash Used in Operating Activities | $(51,828) | $(51,117) |
Liquidity: As of December 31, 2025, the company held $59.1 million in cash and cash equivalents. Management estimates this capital is sufficient to fund operations into the fourth quarter of 2026. The company entered into an "at-the-market" sales agreement in November 2025 to sell up to $16.0 million of common stock, though no shares had been issued as of the filing date.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $6.8 million (13%) from 2024 to 2025, driven primarily by higher operating expenses.
- Operating Expenses: Total operating expenses rose by $8.6 million.
- Research and Development (R&D): Increased by $4.5 million to $48.3 million, primarily due to a $3.6 million increase in personnel costs (including $2.6 million in share-based compensation) and higher clinical trial expenses.
- General and Administrative (G&A): Increased by $4.1 million to $14.7 million, driven by a $3.8 million increase in personnel costs (including $3.6 million in share-based compensation) and higher professional fees, partially offset by a decrease in legal costs related to the 2024 merger.
- Interest Income: Increased by $1.4 million to $3.4 million due to higher cash balances available for investment in 2025.
- Cash Position: Cash and cash equivalents decreased by approximately $51.7 million year-over-year, reflecting the net cash burn from operations.
Guidance, Outlook, and Risks
Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements due to recurring losses and the need for additional capital to fund clinical development.
Clinical Outlook:
- OKI-219 (PIKture-01 Trial): The Phase 1 trial is ongoing. Enrollment for Part A (monotherapy) and Part B (fulvestrant combination) is complete. The company is currently enrolling Part C (trastuzumab/tucatinib combination) and Part E (ribociclib/fulvestrant combination).
- Data Readouts: The company expects to report data from the monotherapy and fulvestrant combination arms, along with initial data from the triplet expansion arms, in 2026.
- Pipeline: The company plans to announce a pan-mutant PI3Kα development candidate in the first quarter of 2026 and expects to provide updates on its vascular malformations program in 2026.
Key Risks:
- Capital Requirements: The company requires substantial additional funding to complete clinical development and commercialization. Failure to secure capital could force delays or termination of programs.
- Clinical Uncertainty: There is no guarantee that OKI-219 will demonstrate sufficient safety and efficacy to obtain regulatory approval. Preliminary data from 2024 showed a favorable safety profile, but efficacy data is pending.
- Competition: The company faces competition from approved PI3Kα inhibitors (e.g., alpelisib, inavolisib) and other investigational therapies.
- Regulatory: Changes in FDA policies or leadership could impact review timelines and approval standards.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management estimate that current cash ($59.1M) will sustain operations into Q4 2026, given the burn rate of ~$52M annually.
- Capital Raising: Monitor the status of the $16.0M "at-the-market" offering and any potential follow-on equity or debt financings required to bridge the funding gap beyond late 2026.
- Clinical Data: Await the 2026 data readout for the PIKture-01 trial, specifically focusing on efficacy signals in the combination arms (Parts C and E) and confirmation of the safety profile (lack of hyperglycemia) in larger cohorts.
- Going Concern Status: Review future filings for any updates on the "substantial doubt" regarding the company's ability to continue as a going concern.
- Pipeline Expansion: Confirm the announcement of the pan-mutant PI3Kα candidate in Q1 2026 as planned.